H.C. Wainwright raised the firm’s price target on Avidity Biosciences (RNA) to $87 from $68 and keeps a Buy rating on the shares. The firm says the EXPLORE44/EXPLORE44-OLE one year data showed reversal of disease progression across all key functional endpoints, not just slowing decline. It continues to believe del-zota’s “differentiated” mechanism of action could set a new standard in exon skipping.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA: